Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)||1:50-1:100|
|Pretreatment||Citrate Buffer pH 6.0|
|Incubation Parameters||30 min at Room Temperature|
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-Bcl-2 Oncoprotein Antibody Clone: EP36
Host and Isotype: Rabbit IgG
Recommended Positive Control Sample: Tonsil, Follicular Lymphoma
Cellular Localization of Antibody EP36 Staining: Cytoplasm
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: A synthetic peptide corresponding to residues between BH3 and BH4 of human Bcl-2 protein
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
Bcl-2 Oncoprotein Information for Pathologists
Summary:BCL2 is a proto-oncogene at locus 18q21.3 the plays a role in inhibiting apoptosis. The BCL2 protein has a M.W. of 25 kDa.
Common Uses By Pathologists:BCL2 staining is used to distinguish follicular hyperplasia of lymph node (germinal centers are BCL2 negative) from follicular lymphoma (germinal centers are BCL2 positive). However, there are reported cases of follicular lymphomas that are BCL2 negative (Am J Surg Pathol 2011;35:1691, Am J Surg Pathol 2009;33:591). BCL2 staining can also identify immature enteric ganglion cells in pediatric intestinal pseudo-obstruction (Am J Surg Pathol 2005;29:1017). BCL2 antibodies label diffuse large cell lymphoma which is an adverse prognostic factor in some studies (Mod Pathol 2005;18:1113, Clin Cancer Res 2011;15:7785). Myelodysplastic syndrome patients should be screened for BCL2 as increased expression is associated with progression. Finally, BCL2 may have prognostic value in early stage breast cancer (Br J Cancer 2010;103:668).
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.